CSTL Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
102.9M
-0.6%
103.5M
+23.7%
83.7M
-3.8%
87.0M
+4.8%
83.0M
Cost of Revenue
23.9M
+0.9%
23.7M
+15.4%
20.5M
+12.1%
18.3M
-2.1%
18.7M
Gross Profit
79.0M
-1.1%
79.8M
+26.4%
63.1M
-8.1%
68.7M
+6.8%
64.3M
Operating Expenses
81.7M
-1.5%
82.9M
+1.7%
81.6M
+12.5%
72.5M
+1.9%
71.1M
R&D
15.8M
+8.7%
14.5M
+0.8%
14.4M
+6.8%
13.5M
+4.3%
13.0M
SG&A
63.8M
-3.5%
66.1M
+1.9%
64.9M
+14.4%
56.7M
+1.5%
55.9M
Operating Income
-2731000
+11.0%
-3070000
+83.3%
-18407000
-381.0%
-3827000
+43.8%
-6804000
EBITDA
1.4M
+44.8%
1.0M
+106.9%
-14478000
-28856.0%
-50000
+98.3%
-2988000
Net Income
-4100000
-99.0%
-2060000
+85.8%
-14522000
-522.7%
-2332000
-365.5%
-501000
EPS (Basic)
$-0.13
-85.7%
$-0.07
+85.7%
$-0.49
-512.5%
$-0.08
-300.0%
$-0.02
EPS (Diluted)
$-0.13
-85.7%
$-0.07
+85.7%
$-0.49
-512.5%
$-0.08
-300.0%
$-0.02
Shares (Diluted)
30.6M
+0.8%
30.4M
+1.7%
29.9M
+4.1%
28.7M
-1.2%
29.1M
Castle Biosciences (CSTL) — Financials